ANTURANE
LOE ApproachingNDAORALTABLET
Approved
May 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTURANE is an oral small-molecule tablet approved in 1959 by Novartis, making it a legacy NDA product with a well-established clinical history. The specific indication and mechanism of action are not disclosed in available data, but the product remains in active distribution. As an older therapeutic, it represents a mature market position with limited expansion potential.
LOE Approaching
Product faces loss of exclusivity with moderate competitive pressure (30); team likely focused on generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ANTURANE offers limited career growth but provides valuable experience in managing mature asset transition and operational efficiency in a declining commercial environment. Roles are typically smaller, focused, and administrative rather than strategic or innovative.
Brand Manager (Generic Transition)Regulatory Affairs Specialist
Worked on ANTURANE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.